Expression, characterization and purification of simian immunodeficiency virus soluble, oligomerized gp160 from mammalian cells

1 Celltech Ltd, 216 Bath Road, Slough, Berkshire SL1 4EN and The 2 Wellcome Foundation, Department of Molecular Sciences, Wellcome Research Laboratories, Langley Court, Beckenham, Kent BR3 3BS, U.K. The envelope glycoprotein, gp160, of human (HIV) and simian (SIV) immunodeficiency viruses mediates v...

Full description

Saved in:
Bibliographic Details
Published inJournal of general virology Vol. 75; no. 1; pp. 207 - 213
Main Authors Rhodes, Andrew D, Spitali, Mariangela, Hutchinson, Gillian, Rud, Erling W, Stephens, Paul E
Format Journal Article
LanguageEnglish
Published Reading Soc General Microbiol 01.01.1994
Society for General Microbiology
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:1 Celltech Ltd, 216 Bath Road, Slough, Berkshire SL1 4EN and The 2 Wellcome Foundation, Department of Molecular Sciences, Wellcome Research Laboratories, Langley Court, Beckenham, Kent BR3 3BS, U.K. The envelope glycoprotein, gp160, of human (HIV) and simian (SIV) immunodeficiency viruses mediates virus-host cell binding followed by fusion of the viral and plasma membranes. The envelope proteins are known to exist as non-covalently associated oligomers on the virus surface. The production of permanent mammalian cell lines that constitutively secrete relatively high levels of soluble forms of SIV gp160 is described and we show that these proteins are secreted predominantly as tetramers with lower levels of dimer forms. Oligomeric forms were purified to greater than 90% purity using a simple gel filtration method. The purified proteins bind CD4 suggesting that they remain in their native conformation. The purified oligomeric proteins provide the basis for more relevant structural, functional and immunological studies than recombinant gp120 as they more closely resemble the envelope protein oligomer. Present address: The Wellcome Foundation, Department of Biochemical Sciences, Wellcome Research Laboratories, Langley Court, Beckenham, Kent BR3 3BS, U.K. Received 23 June 1993; accepted 8 September 1993.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Article-1
ObjectType-Feature-2
ISSN:0022-1317
1465-2099
DOI:10.1099/0022-1317-75-1-207